Prognostic role of survivin in patients with glioma

BACKGROUND: The aim of this study was to systematically evaluate the prognostic role of survivin in patients with glioma through performing a meta-analysis. METHODS: PubMed, Web of Science, Cochrane Library, and EMBASE were searched for potentially eligible literature. The study characteristics and relevant data were extracted. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to estimate the prognostic role of survivin in patients with glioma. RESULTS: Sixteen studies with 1260 patients were included. The pooled HR of higher survivin expression for overall survival was 1.96 (95% CI, 1.57–2.45). The pooled HRs of higher survivin expression for progression- and disease-free survival were 1.62 (95% CI, 0.91–2.90) and 2.41 (95% CI, 0.98–5.90), respectively. Subgroup analyses were also performed. CONCLUSION: Our results suggested that higher survivin expression was associated with worse overall survival in patients with glioma. The findings may assist future exploration on pathogenesis, diagnosis, anti-survivin therapy, and prognosis in glioma. However, due to the limited study number, more studies are warranted to verify our results.